Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Case Studies
AstraZeneca Plots China Robot Offensive to Counter Price Cuts(9/19/2018 )  (Premium)
  "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.
Fosun Pharma Sees 'Huge' Opportunities in India, Southeast Asia, Africa(9/18/2018 )  (Premium)
  Forbes Staff Russell Flannery interviewed Fosun Pharma Chairman Chen Qiyu recently about trends in the pharmaceutical industry and how India fits into his business.
Editor´s Picks
Impending Tariffs on China to Impact Manufacturers of Dietary Supplements, OTC Drugs and Cosmetics(9/21/2018 )  (Premium)
  Newly approved tariffs would impose 10 to eventual 25% tariffs on hundreds of chemical ingredients imported from China used for many FDA-regulated products, including dietary supplements, OTC drugs, and cosmetics, according to this article by legal experts of Morgan Lewis & Bockius LLP.
Should You Look At China For Your Next Clinical Trial?(9/20/2018 )  (Premium)
  Recent regulatory reforms have shortened the timeline to approval and increased investment in the country. Ed Miseta, Chief Editor of Clinical Leader, spoke to three experts to learn how the regulatory changes are impacting trials, and why China should be considered for future trials.
R&D Cooperation Between China and Western Pharma Companies Up 70%(9/18/2018 )  (Premium)
  Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there, a BioSpace article by Alex Keown suggests.
The Market
Nicholas Hall Reports Growth of Chinese OTC Dermatologicals Market in MAT 06/2018(9/20/2018 )  (Premium)
  The Chinese OTC dermatological sales fell 1% in the 12 months to June 2018. Such sales were down owing to reverse switch of Ketoconazole in the country. Meanwhile, foreign players stepped up A+P and launch activities, as the Chinese government¡¯s childbearing push raise hope to boost sales of OTCs for women¡¯s intimate health.
Industry News
China Medical System Signs License and Partnership Deal with VAXIMM AG(9/20/2018 )  (Premium)
  China Medical System Holdings said a unit signed a license and collaboration agreement with Swiss/German biotech company VAXIMM AG, giving it rights to develop and commercialize VAXIMM's pharmaceutical products (the current leading product is oral T-cell immunotherapy VXM01) in China and certain other Asian countries.
Allergan to Build First Medical Aesthetics Innovation Center in China(9/20/2018 )  (Premium)
  Allergan and the Chengdu government signed the investment agreement of establishing Allergan's China Medical Aesthetics Innovation Center. With a total investment of more than US$14.7million, the center is scheduled to open to the public in early 2019 and will train more than 3,000 medical aesthetics professionals every year.
BeiGene Selects GE's KUBio for Its mAb Facility in Guangzhou(9/20/2018 )  (free)
  BeiGene has selected GE Healthcare¡¯s off-the-shelf biomanufacturing facility, KUBio, for large-scale production of its mAbs. The KUBio will be located in Guangzhou. The first phase of the facility is expected to be completed and operational in 2019.
Wuxi AppTech Submitted $1B+ IPO Application in Hong Kong(9/20/2018 )  (Premium)
  WuXi AppTec Co. has submitted an application for listing in Hong Kong, just months after it floated Shanghai IPO. The financial terms of the offering remains undisclosed. However, the offering could raise over US$1 billion, said Bloomberg citing people familiar with the matter.
Roche Announces Plan to Build An Innovation Center in Shanghai(9/20/2018 )  (Premium)
  Swiss pharmaceutical giant Roche announced it will build a CNY 863 million ($125.87 million) innovation center in Shanghai's Pudong New Area. Set to open in 2019, it will be the company's third-largest strategic center after those in Switzerland and the United States.
Merck Slashes Price of Anticancer Keytruda for China Launch(9/19/2018 )  (Premium)
  MSD will cut sharply the price of one of its core cancer drugs for China launch, following the lead by rival BMS for its Opdivo. MSD has developed a patient financial assistance program for Keytruda under which patients who pay for three months of treatment will get the next three months free, resulting in a 50% price reduction.
Lilly China and Microsoft Enter Digital Health Partnership Using AI to Empower Medical Innovation in China(9/19/2018 )  (Premium)
  Lilly China and Microsoft China reached a strategic partnership deal for digital health on September 18. The two parties will join hands in the areas of service, technology and market to build a new ecosystem of artificial intelligence + healthcare.
Novartis and Tencent Enters Strategic Partnership for Digital Medicine(9/19/2018 )  (Premium)
  Novartis China signed a memorandum of cooperation with Tencent Holdings in Shanghai on September 18. The two will jointly develop medical innovations and create new digital treatments and healthcare services using advanced web-based technology.
Novo Nordisk to Axe 400 Research Staffs in Demark and China As It Refocuses R&D(9/18/2018 )  (Premium)
  Novo Nordisk rolled out a new plan on September 18 to revamp its global R&D operations, slashing 400 R&D jobs in Denmark and China as it sets up new ¡°biotech-like¡± research units in key hubs aimed at helping them line up new collaborations in key disease fields.
Congenica Announces Market Access Partnership with Digital China Health(9/18/2018 )  (free)
  The new partnership will see Congenica develop a version of its Sapientia platform designed to enable clinicians and patients in China to benefit from the clinical genomics and personalised medicine revolution.
Regulatory News
CPA Releases Announcement for Excessively-Supplied Drug Products (4th Batch)(9/21/2018 )  (Premium)
  The Chinese Pharmaceutical Association (CPA), entrusted and on behalf of the NMPA, published on September 20 the Announcement for Reminder Information of Excessively-Supplied Drug Products (4th Batch), which contains a total of 297 drugs in 14 therapeutic categories and 60 therapeutic subclasses. Compared with the 3rd batch, the new list added seven drugs and remove eight drugs.
CDE Solicits Comments on Core Considerations for Clinical Protocol Design of Adalimumab Biosimilar(9/20/2018 )  (Premium)
  The CDE released a notice on September 18 to solicit public comments on its draft technical guideline, Core Considerations for Clinical Protocol Design of Adalimumab Biosimilar. Comment period is one month from the date of draft release.
CDE Seeks Comments on Draft Chinese Translations of Seven ICH Guidelines(9/20/2018 )  (Premium)
  The Center for Drug Evaluation under the NMPA, in line with ICH requirement, is now seeking public comments for the Chinese translations of seven ICH Guidelines, including E2F & E2F(R1), E11, E17, E18, Q11, S3A and S9.
General Health
NHC Issues Numerous Clinical Guidelines(9/21/2018 )  (Premium)
  The NHC has recently issued a number of clinical guidelines to provincial level governments for implementation and they include: 1) Clinical Guidelines for New Types of Anticancer Drugs (2018); 2) Diagnostic and Clinical Guidelines for Cancer Pain (2018); and 3) Three documents for clinical application of Carbapenem Antibiotics.
Fitch: Increased Use of Technology Will Improve Healthcare Access in China(9/21/2018 )  (Premium)
  According to a recent Fitch Solutions article, the need for Chinese hospitals to meet growing medical demand will draw them towards technology to enhance efficiency. Besides, various state-level guidelines will further encourage the use of disruptive technology and AI will transform and drive a more patient-centric healthcare system.
State Council Introduces New Policy to Improve the National Essential Drug System(9/19/2018 )  (Premium)
  The General Office of the State Council issued a new policy, Opinions for Further Improving the National Essential Drug System, on September 19. WiCON | Pharma China has prepared an extensive summary of it for our subscribers exclusively.
NHC Issues Regulation to Improve Health and Medical Big Data Management(9/18/2018 )  (Premium)
  The commission plans establish a working mechanism for the opening and sharing of health and medical big data, and administer the building of data reporting platforms, information resources directories, and a system of data sharing and exchanges, according to an announcement on its website.
NHC Issues the Provisions for Clinical Application of Medical Technologies(9/17/2018 )  (Premium)
  The NHC issued the Provisions for Clinical Application of Medical Technologies (NHC Order #1) with effect from November 1, 2018. Technologies for human organ transplantation, assistant reproductive technology and cell therapy technology are not applicable to this regulation.
NHC Issues Three New Rules to Guide and Regulate Development of Internet Medicine(9/17/2018 )  (Premium)
  The National Health Commission (NHC) released on September 14 three new documents, Rules for Internet Medical Practices (Interim), Rules for Internet Hospitals (Interim) and Guidelines for Telemedicine Services (Interim), which are for trial use, detailing the management of online therapy, Internet hospitals and telemedicine.
Product/R&D News
Innovent Reports Clinical Data of Sintilimab as First-line NSCLC Treatment(9/20/2018 )  (Premium)
  In this phase 1b clinical trial patients suffering from first-line ns-NSCLC were treated with sintilimab in combination with pemetrexed (Alimta) and cisplatin. The combination demonstrated an ORR of 68.4%, based on data from 19 patients with at least one radiological assessment among totally the 21 patients in this cohort.
CBT Pharma Initiates the APOLLO Oncology Clinical Trials Program(9/18/2018 )  (Premium)
  The APOLLO series of trials will evaluate and investigate whether CBT¡¯s proprietary assets can work in concert with other agents to improve single agent immunotherapy response rates, and, ultimately, to confer clinical benefit to patients with cancer.
People in the News
Recent Executive Moves(9/21/2018 )  (Premium)
  Recent Chinese pharma-related executive movements at companies including Roche, AstraZeneca China, Servier China, Eli Lilly China, GE Healthcare China and Zion Mediciine.
Top News Worldwide
Top 25 Global Pharmaceutical Companies by Market Cap 2018(9/18/2018 )  (Premium)
  The collective Mcap of the top pharma companies reached roughly $2.7 trillion, with growth at 1.1 percent in Q2 2018. The leading companies¡ªMerck US, Bayer, GSK, Eli Lilly, CSL, and Shire¡ªachieved double digit Mcap growth during the same period.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links